Caribou Biosciences Inc., a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its financial results for the second quarter of 2025. The company reported a net loss of $54.1 million, compared to a net loss of $37.7 million for the same period in 2024. Revenue from licensing and collaboration agreements reached $2.7 million, down from $3.5 million in the previous year. Caribou's non-GAAP net loss, which excludes $21.3 million of non-cash impairment charges, was $32.8 million. The company ended the quarter with $183.9 million in cash, cash equivalents, and marketable securities, a decrease from $249.4 million at the end of 2024. Despite this, Caribou expects its current financial resources to sustain its operating plan into the second half of 2027. In addition to financial figures, Caribou provided updates on its oncology clinical programs, CB-010 and CB-011, with significant data disclosures anticipated in the second half of 2025.